Gutartige und präinvasive Läsionen der Brust

M. R. Bani; E. Wenkel; A. Dimmler; B. Gerber; U. Krainick-Strobel; R. Schulz-Wendtland; P. A. Fasching; M. W. Beckmann

doi:10.1055/s-2007-960680

Frauenheilkunde up2date, Inhaltsverzeichnis

Frauenheilkunde up2date 2007; 1(2): 129-149
DOI: 10.1055/s-2007-960680

Allgemeine Gynäkologie und gynäkologische Onkologie

Gutartige und präinvasive Läsionen der Brust

M. R. Bani¹ , E. Wenkel² , A. Dimmler³ , B. Gerber⁴ , U. Krainick-Strobel⁵ , R. Schulz-Wendtland² , P. A. Fasching¹ , M. W. Beckmann¹

¹Frauenklinik des Universitätsklinikums Erlangen
²Radiologisches Institut des Universitätsklinikums Erlangen
³Pathologisches Institut des Universitätsklinikums Erlangen
⁴Frauenklinik der Universität Rostock
⁵Frauenklinik der Universität Tübingen

Abstract

Alle Artikel dieser Rubrik

Volltext

Referenzen

Literatur

1 Bonk U. Results of the first mammography screening projects in Germany from a histopathological viewpoint. Breast Care. 2006; 1 28-32
2 Collins L C. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Cancer. 2005; 103 9
3 Dupont W D. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Human Pathol. 1989; 20 723-725
4 Dupont W D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985; 312 146-151
5 Elmore J G. Benign breast disease – the risks of communicating risk. N Engl J Med. 2005; 353 297-299
6 Hartmann L C. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005; 353 229-237
7 Lakhani S R. The diagnosis and management of pre-invasive breast disease-current challenges, future hopes. Breast Cancer Res. 2003; 5 248-249
8 Morrow M. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin. 2002; 52 256-276
9 Namba R. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res. 2005; 7 881-889
10 Ozanne E M. Breast cancer risk assessment and prevention. Breast J. 2006; 12 103-113
11 Page D L. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003; 361 125-129
12 Page D L. Atypical hyperplastic lesions of the female breast. Cancer. 1985; 55 2698-2708
13 Perry N M. Quality assurance in the diagnosis of breast disease. Eur J Cancer. 2001; 37 159-172
14 Pinder S E. Ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) – current definitions and classification. Breast Cancer Res. 2003; 5 254-257
15 Santen R J. Benign breast disorders. N Engl J Med. 2005; 353 275-285
16 Simpson P T. Pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003; 5 258-262
17 Schnitt S J. Benign breast disease and breast cancer risk. Am J Pathol. 2003; 27 836-841
18 Silverstein M J. Ductal carcinoma in situ. Breast. 2003; 12 457-471
19 Tavassoli F A. Breast pathology. Nature clinical practice oncology. 2005; 2 3
20 Tavassoli F A. Ductal intraepithelial neoplasia of the breast. Virchows Arch. 2001; 438 221-227
21 Van de Vijver M J. Pathological diagnosis – problems with existing classifications. Breast Cancer Res. 2003; 5 269-275
22 Wang J. Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst. 2004; 96 616-620
23 Warren J L. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS. Cancer. 2005; 104 1840-1848
24 Deutsche Krebsgesellschaft .S 3-Leitlinien. ███

Dr. med. M. R. Bani

Frauenklinik des Universitätsklinikums Erlangen

Universitätsstraße 21–23

91054 Erlangen

eMail: direktion@gyn.imed.uni-erlangen.de